Nucleic Acids Encoding Antibody Molecules Which Bind IL-17A and IL-17F
The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
1 - 37 . (canceled)
38 . A neutralising antibody which binds human IL-17A and human IL-17F, comprising a heavy chain wherein a variable domain of the heavy chain comprises a sequence given in SEQ ID NO:1 for CDR-H1, a sequence given in SEQ ID NO:2 for CDR-H2 and a sequence given in SEQ ID NO:3 for CDR-H3.
39 . The neutralising antibody which binds human IL-17A and human IL-17F according to claim 38 , additionally comprising a light chain, wherein a variable domain of the light chain comprises a sequence given in SEQ ID NO:4, for CDR-L1, a sequence given in SEQ ID NO:5 for CDR-L2 and a sequence given in SEQ ID NO:6 for CDR-L3.
40 . A neutralising antibody which binds human IL-17A and human IL-17F, wherein a heavy chain comprises a sequence given in SEQ ID NO:9 or a sequence at least 90% identical thereto.
41 . The neutralising antibody according to claim 40 , additionally comprising a light chain, wherein the light chain comprises a sequence given in SEQ ID NO:7 or a sequence at least 90% identical thereto.
42 . The neutralising antibody according to claim 39 , having the heavy chain comprising a sequence given in SEQ ID NO:9 and the light chain comprising the sequence given in SEQ ID NO:7.
43 . A neutralising antibody which binds human IL-17A and human IL-17F, having a heavy chain comprising a sequence given in SEQ ID NO:15 or a sequence at least 95% identical thereto and a light chain comprising a sequence given in SEQ ID NO:11 or a sequence at least 95% identical thereto.
44 . The neutralising antibody which binds human IL-17A and human IL-17F and which binds to a same epitope on human IL-17A and human IL-17F as the antibody of claim 42 .
45 . The neutralising antibody which binds human IL-17A and human IL-17F which cross-blocks the binding of the antibody of claim 42 to human IL-17A and/or human IL-17F and/or IL-17A/F heterodimer and/or is cross-blocked from binding human IL-17A and/or human IL-17F and/or IL-17A/F heterodimer by the antibody of claim 42 .
46 . The neutralising antibody of claim 38 , wherein the antibody is a whole antibody or a functionally active fragment or derivative thereof.
47 . The neutralising antibody according to claim 46 where the antibody fragment is a domain antibody, Fab, Fab′, F(ab′) 2 , scFv or an epitope-binding fragment thereof.
48 . The neutralising antibody according to claim 47 , wherein the antibody or fragment thereof is a CDR-grafted antibody or a fully human antibody.
49 . The antibody of claim 38 , wherein the antibody or fragment thereof is conjugated to one or more effector molecule(s).
50 . An isolated DNA sequence encoding the heavy and/or light chain(s) of an antibody of claim 38 .
51 . A cloning or expression vector comprising one or more DNA sequences according to claim 50 .
52 . The vector according to claim 51 , wherein the vector comprises a sequence given in SEQ ID NO:18.
53 . The vector according to claim 52 , wherein the vector comprises a sequences given in SEQ ID NO:14 and the sequence given in SEQ ID NO:18.
54 . A host cell comprising one or more cloning or expression vectors according to claim 51 .
55 . A process for the production of the antibody of claim 38 , comprising culturing the host cell of claim 54 and isolating the antibody.
56 . A pharmaceutical composition comprising an antibody of claim 38 , in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.
57 . The pharmaceutical composition according to claim 56 , additionally comprising other active ingredients.
58 . The antibody of claim 38 or a pharmaceutical composition according to claim 56 , for use in the treatment or prophylaxis of a pathological disorder that is mediated by IL-17A and/or IL-17F or that is associated with an increased level of IL-17A and/or IL-17F.